Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Compass Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 92 | 1 | 108 | +17 |
| Shares | 101.4M | 304.5K | 108.5M | +7.40M (+7.3%) |
| Value | $147.0M | $441.5K | $206.1M | +$59.5M (+40.6%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (27)
Institutions that held Compass Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (10)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| CM Management, LLC | 310,000 | $449.5K |
| DAFNA Capital Management LLC | 158,394 | $229.7K |
| Connor, Clark & Lunn Investment Management Ltd. | 156,871 | $227.5K |
| XTX Topco Ltd | 52,754 | $76.5K |
| Two Sigma Advisers, LP | 51,000 | $74.0K |
| Bleakley Financial Group, LLC | 39,993 | $58.0K |
| Squarepoint Ops LLC | 24,072 | $34.9K |
| Algert Global LLC | 22,588 | $32.8K |
| Two Sigma Securities, LLC | 13,887 | $20.1K |
| Victory Capital Management Inc | 10,536 | $15.3K |
Not filed for Q1 2025 yet (1)
Institutions that held Compass Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 304,504 | $441.5K |